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rs57025206, BRCA1 all + +C/C CTTTCTGCAG
452 1217 969 753
34 64 41 29CTTTCTGCAG
C/C


















Supplementary Figure 1. The survival effect associated with rs57025206 in all BRCA1 carriers.
a) Kaplan-Meier plot stratified by rs57025206. b) Forest plot of hazard ratios (HR) accross country groups.







Manhattan plots from survival-association analyses of a) BRCA1 carriers, b) BRCA1 carriers with ER-negative breast cancer, c) BRCA2 carriers, d) BRCA2 carriers from variant-
diagnosis age interaction analysis, and e) a meta-analysis of nominal survival associations in BRCA1 and BRCA2 carriers. P-values from likelihood ratio test plotted against 
genomic position. (Green dashed line: 5·10-8; blue dashed line: 5·10-7) 
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rs12126206, BRCA1 all + +T/T T/A or A/A
414 1113 862 673
66 168 148 109T/A or A/A
T/T
Number at risk



































rs5028286, BRCA1 all + +A/A A/G or G/G
397 1040 808 641
84 241 202 141A/G or G/G
A/A
Number at risk



































rs736418, BRCA1 all + +A/A A/G or G/G
294 756 585 465
188 525 425 317A/G or G/G
A/A
Number at risk








































rs147857072, BRCA1 all + +T/T T/C or C/C
468 1257 997 772
32 24 13 10T/C or C/C
T/T
Number at risk
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rs59010985, BRCA1 all + + +C/C C/T T/T
333 907 691 534
134 337 290 231








































rs34987256, BRCA1 all + + +G/G G/GT GT/GT
76 177 156 125
256 694 542 411



















































rs11245414, BRCA1 ER−negative + + +A/A A/T T/T
12 20 16 8
67 198 146 91




































rs1829314, BRCA1 ER−negative + +C/C C/T or T/T
187 618 452 285























rs78150318, BRCA1 ER−negative + +C/C C/T or T/T
191 620 442 275
19 37 36 26C/T or T/T
C/C
Number at risk
Supplementary Figure 3. Plots for survival variants discovered in BRCA1 carriers
Kaplan-Meier curves graphically presenting the proportion of surviving patients during the 15 years after primary breast cancer diagnosis in the discovery data (see Table 2), stratified by the 10 BRCA1-associated 
survival variants (1st and 3rd panel from left). Forest plots presenting the effect sizes in different country groups (2nd and 4th panel). Because the carriers of effect alleles of rs1829314 and rs78150318 had no 
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rs551383190, BRCA1 all + + +A/A A/C C/C
362 965 741 561
118 298 249 207













































rs551383190, BRCA2 all + + +A/A A/C C/C
187 648 496 296
83 206 179 128










































rs117422049, BRCA1 all + +G/G G/A or A/A
470 1255 992 767
14 27 21 15G/A or A/A
G/G
Number at risk










































rs117422049, BRCA2 all + +G/G G/A or A/A
265 853 686 429
9 17 7 9G/A or A/A
G/G
Number at risk




































rs4879914, BRCA1 all + + +T/T T/C C/C
83 257 217 169
252 618 499 386









































rs4879914, BRCA2 all + + +T/T T/C C/C
68 204 169 97
127 416 334 211
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rs2320070, BRCA1 all + + +C/C C/T T/T
36 82 65 47
173 524 422 330
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rs2320070, BRCA2 all + + +C/C C/T T/T
26 56 49 33
110 357 280 192

















Supplementary Figure 4.Plots for survival variants discovered in the meta-analysis
Kaplan-Meier curves stratified by the four variants with consistent survival effects for BRCA1 and BRCA2 carriers (1st and 3rd panel from the left, respectively). Forest plots presenting the effect sizes in 
































rs372812554, BRCA2, Age <= 40 + + +T/T T/TTTA TTTA/TTTA
51 157 124 95
36 113 82 62
































rs372812554, BRCA2, 40 < Age <= 50 + + +T/T T/TTTA TTTA/TTTA
52 186 152 86
43 144 115 74
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rs372812554, BRCA2, Age > 50 + + +T/T T/TTTA TTTA/TTTA
42 133 98 52
47 84 75 47


































rs2109815, BRCA2, Age <= 40 + + +G/G G/A A/A
53 158 122 93
29 106 89 57






























rs2109815, BRCA2, 40 < Age <= 50 + + +G/G G/A A/A
54 194 160 86
42 130 104 74
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rs2109815, BRCA2, Age > 50 + + +G/G G/A A/A
45 124 102 61
42 92 73 36































rs35431863, BRCA2, Age <= 40 + + +GA/GA GA/G G/G
22 74 50 45
48 132 124 81




























rs35431863, BRCA2, 40 < Age <= 50 + + +GA/GA GA/G G/G
27 94 99 50
51 176 122 84






























rs35431863, BRCA2, Age > 50 + + +GA/GA GA/G G/G
36 62 48 29
63 112 95 51
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rs11255420, BRCA2, Age <= 40 + + +C/C C/T T/T
71 168 125 95
33 100 85 55
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rs11255420, BRCA2, 40 < Age <= 50 + + +C/C C/T T/T
65 209 160 103
38 130 108 58





































rs11255420, BRCA2, Age > 50 + + +C/C C/T T/T
53 124 109 73
38 98 72 29




Supplementary Figure 5.Plots for survival variants discovered in BRCA2 carriers
Kaplan-Meier curves stratified by the four variants with age-dependent survival effect for BRCA2 carriers in three age-groups: patients diagnosed before the age of 40 years (left), 
between the age of 40 and age of 50 years (middle), and after the age of 50 years (right).
6
  7 













          BRCA1 BRCA2 BRCA1 BRCA2 
BCFR-AU Australian site of the Breast Cancer Family Registry Australia Australia Population based 25  8  
BCFR-NC Northern California site of the Breast Cancer Family Registry USA USA Population based 31  6  
BCFR-ON/ 
OCGN 
Ontario site of the Breast Cancer Family Registry/ 
Ontario Cancer Genetics Network 
Canada Canada 
Clinic and  
population based 
73 53 15 17 
CBCS Copenhagen Breast Cancer Study Denmark Denmark Clinic based 73 63 14 9 
COH City of Hope Cancer Center USA USA Clinic based 101  15  
DEMOKRITOS National Centre for Scientific Research Demokritos Greece Balkan Clinic based 57  9  
DFCI Dana Farber Cancer Institute USA USA Clinic based 64 46 8 8 
EMBRACE Epidemiological Study of Familial Breast Cancer UK UK Clinic based 694 678 95 89 
GC-HBOC German Familial Breast Group Germany Central-Europe Clinic based 368 207 33 17 
HEBCS Helsinki Breast Cancer Study Finland Scandinavia Clinic based 62 61 18 16 
HEBON Hereditary Breast and Ovarian cancer study the Netherlands Netherlands Netherlands Clinic based 234 93 41 28 
ICO Institut Català d’Oncologia Spain Iberia Clinic based 87 100 14 16 
IHCC International Hereditary Cancer Centre Poland East-Europe Clinic based 94  7  
IPOBCS Portuguese Oncology Institute-Porto Breast Cancer Study Portugal Iberia Clinic based 39 82 12 11 
KCONFAB Kathleen Cuningham Consortium for Research into Familial Breast Cancer Australia Australia Clinic based 331 245 53 37 
MUV General Hospital Vienna Austria Central-Europe Clinic based 218 108 38 17 
OUH Odense University Hospital Denmark Denmark Clinic based 172 143 30 27 
SWE-BRCA Swedish Breast Cancer Study Sweden Scandinavia Clinic based 97  19  
UPENN University of Pennsylvania USA USA Clinic based 118 82 13 11 
VFCTG Victorian Familial Cancer Trials Group Australia Australia Clinic based 70 48 13 8 
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Supplementary Table 2. Additional models for BRCA1 carriers. 
Variant effects in multivariate and in breast cancer-specific survival analyses for the SNPs, which were considered novel discoveries in the analysis of BRCA1 carriers and BRCA1 





HR for all-cause 
mortality in a model 
adjusted for tumor 
characteristics 
Nominal HR for 
breast cancer-
specific death 
HR for breast 
cancer-specific 
death in a model 
adjusted for tumor 
characteristics 
      HR [95% CI] HR [95% CI] HR [95% CI] 
rs12126206 BRCA1 all BC dominant 1.96 [1.37-2.81] 1.53 [1.08-2.17] 1.91 [1.07-3.39] 
rs5028286 BRCA1 all BC dominant 1.55 [1.11-2.17] 1.44 [1.04-1.99] 1.21 [0.69-2.10] 
rs736418 BRCA1 all BC dominant 0.60 [0.43-0.83] 0.72 [0.53-0.96] 0.41 [0.24-0.70] 
rs147857072 BRCA1 all BC dominant 4.95 [2.67-9.18] 2.55 [1.41-4.61] 3.32 [1.28-8.58] 
rs59010985 BRCA1 all BC per-allele linear 0.49 [0.34-0.70] 0.61 [0.44-0.83] 0.66 [0.40-1.09] 
rs34987256† BRCA1 all BC per-allele linear 1.44 [1.09-1.89] 1.68 [1.31-2.16] 1.61 [1.04-2.48] 
rs1829314 BRCA1 ER-negative dominant 0.00 [0.00-0.00] 0.00 [0.00-0.00] 0.00 [0.00-0.00] 
rs57025206 BRCA1 ER-negative per-allele linear 6.19 [3.73-10.3] 4.68 [2.81-7.80] 4.98 [1.91-13.0] 
rs11245414 BRCA1 ER-negative per-allele linear 0.68 [0.51-0.91] 0.54 [0.40-0.72] 0.63 [0.41-0.97] 
rs78150318 BRCA1 ER-negative dominant 0.00 [0.00-0.00] 0.00 [0.00-0.00] 0.00 [0.00-0.00] 
†The hazard associated with the SNP did not significantly violate of the proportional hazards assumption in the multivariate models or in the analyses of breast cancer-associated death. 
Supplementary Table 3. Additional meta-analysis models. 
Variant effects in multivariate and in breast cancer-specific survival analyses for the SNPs, which were considered novel discoveries in the BRCA1-BRCA2-carrier meta-analysis. 
SNP Analysis subgroup Genetic 
model 
HR for all-cause 
mortality in a model 
adjusted for tumor 
characteristics 
Nominal HR for 
breast cancer-
specific death 
HR for breast 
cancer-specific 
death in a model 
adjusted for tumor 
characteristics 
      HR [95% CI] HR [95% CI] HR [95% CI] 
rs551383190 BRCA1/BRCA2 per-allele linear 0.61 [0.46-0.82] 0.63 [0.49-0.81] 0.68 [0.50-0.94] 
rs117422049 BRCA1/BRCA2 per-allele linear 3.43 [0.83-14.3] 3.24 [1.97-5.32] 3.60 [2.00-6.47] 
rs4879914 BRCA1/BRCA2 per-allele linear 1.40 [1.18-1.67] 1.39 [1.20-1.60] 1.49 [1.24-1.80] 
rs2320070 BRCA1/BRCA2 per-allele linear 1.31 [1.06-1.63] 1.40 [1.17-1.68] 1.46 [1.02-2.09] 
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Supplementary Table 4. Additional models for BRCA2 carriers. 





HR for all-cause mortality in a model 
adjusted for tumor characteristics 
Nominal HR for breast cancer-specific 
death 
HR for breast cancer-specific death in a 
model adjusted for tumor characteristics 
      dgAge < 40 years dgAge ≥ 40 dgAge < 40 years dgAge ≥ 40 dgAge < 40 years dgAge ≥ 40 
      HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI] 
rs372812554 BRCA2 all BC per-allele interaction with age 2.11 [1.33-3.34] 0.84 [0.57-1.23] 1.91 [1.32-2.76] 0.74 [0.53-1.04] 2.04 [1.09-3.85] 0.66 [0.39-1.12] 
rs2109815 BRCA2 all BC per-allele interaction with age 1.70 [1.09-2.67] 0.92 [0.64-1.32] 1.78 [1.24-2.56] 0.87 [0.64-1.18] 2.01 [1.17-3.46] 1.12 [0.66-1.91] 
rs35431863 BRCA2 all BC per-allele interaction with age 0.58 [0.29-1.14] 1.29 [0.94-1.78] 0.55 [0.38-0.78] 1.27 [0.98-1.65] 0.62 [0.27-1.44] 1.40 [0.94-2.09] 
rs11255420 BRCA2 all BC per-allele interaction with age 0.62 [0.32-1.18] 1.28 [0.87-1.90] 0.67 [0.44-1.01] 1.73 [1.28-2.33] 0.44 [0.19-1.05] 1.29 [0.74-2.24] 
 
Supplementary Table 5. Survival associations of variants with age-dependent survival effect in BRCA2 carriers, stratified by the tumor ER-status. 
SNP ER-positive BRCA2 carriers (n:1067) ER-negative BRCA2 carriers (n: 302) 
 
under  40 years 
HR [95% CI] 
over  40 years  
HR [95% CI] 
under  45 years  
HR [95% CI] 
over  45 years  
HR [95% CI] 
rs372812554 1.67 [1.19 - 2.36] 0.69 [0.49 - 0.98] 1.43 [0.50 - 4.05] 1.40 [0.77 - 2.54] 
rs2109815 1.86 [1.24 - 2.79] 0.75 [0.56 - 1.01] 1.57 [0.84 - 2.93] 0.46 [0.20 - 1.05] 
rs35431863 0.54 [0.37 - 0.80] 1.48 [1.15 - 1.90] 0.97 [0.47 - 2.02] 1.31 [0.71 - 2.41] 
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Supplementary Table 6. Literature-based functional annotation of the target genes. 
Gene Function  Ref. 
KIF26B silencing in breast cancer cell lines reduces colony-formation 1, 2 
  reduces migration and invasion  
  leads to increased E-cadherin expression and reduced N-cadherin expression  
  induces apoptosis  
  aggregates cells in G0/G1 phase  
 overexpression in breast cancer cell lines increases proliferation (increased cell count) 2 
  promotes migration and invasion  
  positively affects FGF2 expression and secretion  
  leads to MAPK/ERK pathway activation  
 knock-down in a xenograft model reduces tumor formation  
  reduces the frequency of lung metastases  
 mRNA expression in mammary tumors is elevated in comparison to adjacent normal 1, 2 
 protein expression in mammary tumors is elevated in comparison to adjacent normal 2 
 mRNA expression in breast cancer cell lines is elevated in comparison to MCF10A non-malignant mammary cells 1 
 high expression in mammary tumors is associated with larger, ER-positive, higher-grade, node-positive tumors, and poor survival 3 
 enhances microtubule stabilization required for asymmetrical cell structure organization and directional migration 4 
 mediates multi-drug resistance in osteosarcoma cells 5 
SGCZ loss in mammary tumors is more frequent in early-onset tumors (METABRIC) 6, 7 
  is associated with poor prognosis  
  does not affect SGCZ mRNA expression in mammary tumors, which is generally very low  
MIR383 is located in intron 1-2 of SGCZ and MIR383 expression is coupled with SGCZ expression 8 
 overexpression in mouse ovarian cells enhances estradiol release from ovaries via repression of RMBS1, and consecutively also MYC  
 overexpression in ovarian cancer cell lines sensitizes the cells to paclitaxel 9 
RALGDS is recruited to endosomal compartments by RILP 10 
 mediates the RILP-dependent inhibition of cell proliferation, migration and invasion  
 serves as a guanine nucleotide exchange factor for Ral  
 interaction with RILP affects the MAPK/ERK pathway  
 does not directly stimulate MAPK/ERK 11 
 induces cytoskeletal reorganization in response to FPR1 stimulation 12 
MBIP was the top-ranking breast cancer risk gene in a genome-wide pathway analysis 13 
GAS7 is hypomethylated (activated) in ER-negative breast cancer in comparison to ER-positive breast cancer 14, 15 
 transcript variant B mRNA expression is low in mammary tumors in comparison to adjacent normal 16 
  is low in early-onset tumors in comparison to late-onset tumors  
  is low in many breast cancer cell lines  
 overexpression in several breast cancer cell lines reduces proliferation, migration and invasion  
 silencing in MCF-7 breast cancer cell line increases proliferation, migration and invasion  
 high expression inhibits actin polymerization via GAS7 – CYFIP1 – Rac1 – WAVE2 complex  
 is regulated by TP53   
 transcript variant B regulatory region co-localizes with the survival variants (Supplementary Table 5)  
 rs59010985 allele T is associated with high GAS7 expression (Table 5, Supplementary Table 6)  
 high mRNA expression is associated with good prognosis of ER-negative breast cancer patients HR = 0.46 [0.37 - 0.58], P = 2.5E-12 (FDR 1%) 17 
  good prognosis of breast cancer patients irrespective of ER-status 7 
  HR per unit fold change in all 0.81 [0.72 – 0.90], P = 1.4E-4, in METABRIC data  
 mediates the apoptotic effects of platinum compounds in hepatocellular carcinoma and neuroblastoma cells 18, 19 
  gefitinib in non-small cell lung carcinoma 20 
 
  11 
Gene Function  Ref. 
CHST9 variant rs1436904 is significantly associated with breast cancer risk in an international consortium study 21 
  is associated with survival of triple-negative breast cancer patients in Chinese population 22 
  is linked with the survival variant rs537497819 with D’=0.1939, R2=0.0188  
DCAF1 is an E3 ubiquitin ligase substrate receptor which brings together the substrate and E2 ubiquitin conjugating ligase 23 
 recognizes the substrate for ubiquitination leading to proteasomal degradation of the substrate  
 substrates include TP53 tumor suppressor, apoptosis regulator  
  ER-alpha via LATS1 interaction 24 
  non-histone proteins monomethylated by EZH2 (component of the polycomb repressor complex) 25 
 silencing in MCF-7 breast cancer cell line reduces colony formation  
 regulates DNA replication 23 
  cell cycle progression  
  entry to mitosis  
  cell division  
  ER-alpha level 24 
  T-cell activation induced proliferation 26 
  T-cell receptor gene reorganization  
  centrosome organization by ubiquitylation as a part of the EDVP complex 27 
MIR135A1 deletion in mammary tumors is associated with higher pathologic stage 28 
  younger age of onset  
  ductal histologic type  
  worse survival outcome  
  lower expression of pri-miR-135-a-1, primary precursor of mir-135A1  
 expression in mammary tumors is higher in ER+ than ER- cancers  
 depletion in breast cancer cell lines increases cell viability, colony formation, migration, and invasion  
  decreases sensitivity to tamoxifen treatment and contributes to acquisition of resistance  
  enhances the activity of MAPK/ERK and PI3K/AKT pathways  
 forced expression in breast cancer cell lines decreases cell viability, colony formation, migration, and invasion  
  enhances epithelial cellular phenotype  
  suppresses the activity of MAPK/ERK and PI3K/AKT pathways  
 level is correlated with epithelial markers  
  inversely with mesenchymal markers  
 forced expression in a mouse model inhibits tumor formation and lung metastasis  
 promoter is bound by ER-alpha   
 directly binds and regulates ER-alpha creating a negative feedback loop  
 expression promotes resistance to oxaliplatin in gastric cancer 29 
  gefitinib in non-small cell lung cancer 30 
3p21.2 loss in mammary tumors is more frequent than loss of any other region in 3p 31, 32 
(DCAF1 and MIR135A1)  is associated with high grade and ER-, PR- tumors  
ZRANB1 regulates EZH2 (component of the polycomb repressor complex) by deubiquitination 33 
 silencing in triple-negative breast cancer cell lines reduces proliferation and migration  
  which can be rescued by overexpressing EZH2  
 silencing in a mouse model suppresses tumor formation and lung metastases  
 silencing in cell lines increases stress fibers and inhibits migration 34 
 expression in normal mammary tissue is very low 33 
 high expression in mammary tumors is associated with poor survival  
 is required for inflammatory T-cell response 35 
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Gene Function  Ref. 
CTBP2 is a transcriptional co-repressor and regulator of Golgi apparatus fission 36 
 primes target genes for repression by PRC2 37 
 regulates Aurora B kinase in early mitosis 36, 38, 39 
  p16, CDH1, PTEN  
  stem-cell like characteristics of ovarian cancer cells  
 silencing in breast cancer cell lines leads to TP53-dependent cell cycle arrest and apoptosis 36, 38, 40 
  causes cell cycle stasis in aberrant mitosis  
  increases the number of binucleate cells and lagging chromosomes  
  suppresses cell migration  
 overexpression in breast cancer cell lines increases cell proliferation and cell accumulation in S-phase 38 
  decreases E-cadherin expression  
  increases vimentin and MMP2 expression  
 overexpression in a mouse xenograft model accelerates tumor growth  
 is expressed ubiquitously in breast cancer cell lines and patient samples 40 
 high expression in mammary tumors is associated with poor survival (ER-negative tumors: HR = 1.72 [1.39 - 2.14], P = 4.5E-7 (FDR 1%)) 17, 38 
 low expression in ovarian tumors is correlated with high infiltration of CD33+ myeloid-derived suppressor cells 39 
  and poor prognosis of ovarian cancer patients  
 proteasomal degradation can be induced by APC, UV-light, or cisplatin 40 
 may mediate the immune suppressive nature of KLGR1+ T cells 41 
 binds to BRCA1 promoter in ovarian cancer cell lines, repressing transcription and affecting sensitivity to PARP inhibitors 42 
 overexpression reduces sensitivity to cisplatin in non-small cell lung and esophageal squamous cell carcinoma 43, 44 
RAD51B variant rs2588809 is associated with breast cancer risk 21, 45 
  is linked with the survival variant rs78150318 with R2=0.0016, D’=0.4677  
 silencing is associated with increased genomic instability 46, 47 
 somatic alterations in BRCA1-defective breast cancer are associated with poor overall survival of patients 48 
CREB5 is repressed by miR-29c to inhibit proliferation in a preneoplastic triple-negative breast cancer model 49 
 high expression in ER-positive mammary tumors is associated with good prognosis with HR = 0.61 [0.50 - 0.74], P = 5.7E-7 (FDR 1%) 17 
ASPH locus is amplified in a subgroup of primary tumors  50 
 becomes upregulated in response to IGF1 exposure via MAPK and PI3K/Akt pathways 51 
 expression is inversely correlated with tamoxifen sensitivity of breast cancer cell lines  
 high expression predicts poor outcome from endocrine therapy for patients with luminal B breast cancer  
 proteins and peptides are highly immunogenic in induced dendritic cells of hepatocellular carcinoma patients 52, 53 
  and may thus be a target for immunotherapy in hepatocellular carcinoma  
GATA3 is a transcription factor  54-56 
 regulates differentiation of mammary gland luminal cells 54, 55, 57 
 silencing in mammary luminal cells blocks differentiation  
  increased proliferation  
  leads to abnormalities nuclear size and orientation  
  causes cell detachment and increased cell death  
 knock-down in mice causes severe defects in mammary gland formation and lactation 54, 55 
 modulates ESR1 binding profile by enabling ESR1 access to chromatin of limited active histone composition 56 
 high expression in mammary tumors is associated with hormone-positive/luminal tumor phenotype and low grade 58-62 
  is associated with good patient prognosis 58, 59, 63-65 
  does not affect prognosis 60, 62 
  is associated with shorter locoregional relapse time in premenopausal patients 66 
  is associated with decreased rate of pathologic complete response to neoadjuvant chemotherapy 61 
  is associated with increased probability of GATA3 somatic mutation 65 
 regulates spindle orientation in prostate epithelial cells 67 
 has diverse roles in differentiation and homeostasis of immune cells 68 
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Gene Function  Ref. 
ZNF644 is a component of G9a/GLP complex which represses transcription via H3K9 methylation 69, 70 
  which interacts with polycomb repressor complex  
  which is a part of the replisome, required to prevent replication-associated DNA damage  
 recognizes the DNA target sequence  69 
 silencing in vitro decreased proliferation 71 
  sensitized to replication stress  
  increased DNA damage in replicating cells  
 high expression in mammary tumors is associated with poor prognosis with HR = 1.43 [1.21 - 1.69], P = 2.2E-5 (FDR 2%) 17 
CLASP1 regulates microtubule dynamics during mitosis 72, 73 
 localizes to the outer region of kinetochore (korona)  
  near the kinetochore-attached microtubule plus-ends  
 knock-down in human and murine cells leads to chromosomal instability 73 
 is required for invasion through 3D matrix 74 
  enhancing compression- resistance of growing microtubules  
 high expression in mammary tumors is associated with good prognosis with HR = 0.71 [0.63 - 0.80], P = 4.9E-9 (FDR 1%) 17 
NIFK nucleolar protein interacting with the FHA domain of MKI67 75 
 overexpression in ling cancer cell lines enhances proliferation, migration, and invasion  
 regulates TCF4/β-catenin via repression of RUNX1 and CK1α  
 high expression in mammary tumors is associated with poor patient survival  
 is phosphorylated by CDK1 and GSK3 76 
 transcription is induced by c-Myc and estrogen  
 knock-down in osteosarcoma cell line induced cell cycle arrest in G1 as a result of ribosomal stress  
 is required for ribosomal RNA maturation especially in ITS1 (internal transcribed spacer 1) processing  
NIFK-AS1 suppresses macrophage M2 polarization; M2 polarized macrophages participate in angiogenesis and promote tumor invasiveness 77 
 overexpression in macrophages suppressed the proliferation of estrogen-stimulated endometrial cancer cells  
 high expression in mammary tumors is associated with good prognosis with HR = 0.64 [0.54 - 0.74], P = 1.5E-8 (FDR 1%) 17 
TFCP2L1 is required for pluripotency of embryonic stem cells 78 
 together with Zf5, Ctcf, E2f1, and Myc predicts the targets of polycomb repressor complex 79 
 low expression in mammary tumors is associated with poor prognosis with HR = 1.41 [1.20 - 1.67], P = 3.1E-5 (FDR 5%) 17 
ARHGEF39 overexpression in gastric and non-small cell lung cancer cell lines induces proliferation, migration, and invasion 80, 81 
  increases Akt phophorylation activating the Akt/PI3K pathway  
  increases P38 and ATF2 phophorylation and activates MAPK pathway  
  increases the cellular levels of Cyclin A2, Cyclin D1, and MMP2  
  increases Rac1 activation  
 knockdown in gastric and non-small cell lung cancer cell lines represses proliferation, migration, and invasion  
TPM2 binds actin to stabilize microfilaments 82 
 in involved in cytokinesis, cellular vesicle transport, proliferation, migration, and apoptosis  
 expression is reduced in breast cancer in comparison to adjacent normal tissue  
  in hypoxic conditions  
 silencing in breast cancer cell lines increases invasion and migration  
  contributes to paclitaxel resistance  
 silencing in HeLa and U2OS cells induces lysosomal destabilization and lysosomal cell death 83 
  sensitizes to cisplatin, siramesine, and etoposide  
 low protein expression in mammary tumors is associated with poor patient survival 82 
 low mRNA expression in mammary tumors is associated with good survival with HR = 0.64 [0.57 - 0.72], P = 2.9E-14 (FDR 1%) 17 
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Gene Function  Ref. 
GBA2 Bile acid b-glucosidase breaks down glucocylceramide (outside lysosomes) 84 
 Multi-drug resistant MCF-7 has high levels of glucocylceramide due to high glucocylceramide synthase activity  
 Glucocylceramide synthase repression increases drug sensitivity in multi-drug resistant MCF-7  
 Overexpression of GBA2 DOES NOT have the same effect in multi-drug resistant MCF-7  
 low expression in mammary tumors is associated with poor survival with HR = 1.58 [1.35 - 1.85], P = 5.6E-9 (FDR 1%) 17 
 silencing leads to accumulation of glucosylceramide in plasma membrane, affecting actin and microtubule dynamics 85 
RUSC2 silencing in lung cancer cell lines reduced directional migration (chemotaxis) 86 
  did not affect random migration (chemokinesis)  
  causes defective Golgi orientation for chemotaxis  
 is required for EGFR-induced GIT2 (G protein-coupled receptor kinase interacting ArfGAP 2) phosphorylation  
  directional cell migration  
CD72 interaction with CD5 is required for regulatory B cell and regulatory T cell reciprocal stimulation 87 
 is a membrane-bound receptor for CD100 in T cells 88 
 interaction with CD100 is required for T cell activation  
TRAV T cell receptor alpha variable region genes   
 
Supplementary Table 7. Survival associations in the Breast Cancer Association Consortium (BCAC) data. 
Variant BCAC: analysis group HR [95% CI] CIMBA: analysis group HR [95% CI] CIMBA: analysis group 2 HR [95% CI] 
rs12126206 ER- 0.95 [0.83-1.08] BRCA1 all BC 1.86 [1.50 - 2.32]   
rs5028286 ER- 1.09 [0.99-1.21] BRCA1 all BC 1.74 [1.42 - 2.12]   
rs736418 ER- 1.01 [0.93-1.09] BRCA1 all BC 0.60 [0.49 - 0.73]   
rs147857072 ER- 1.00 [0.67-1.49] BRCA1 all BC 3.41 [2.32 - 5.00]   
rs59010985 ER- 0.96 [0.87-1.06] BRCA1 all BC 0.58 [0.47 - 0.72]   
rs537497819   BRCA1 all BC 1.49 [1.27 - 1.74]   
rs1829314 ER- 1.10 [0.92-1.31] BRCA1 ER- 0 [0 - 0]   
rs57025206 ER- 1.06 [0.86-1.29] BRCA1 ER- 4.37 [3.03 - 6.30]   
rs11245414 ER- 1.00 [0.93-1.08] BRCA1 ER- 0.56 [0.46 - 0.70]   
rs78150318 ER- 0.94 [0.78-1.15] BRCA1 ER- 0 [0 - 0]   
rs551383190   BRCA1/BRCA2 0.61 [0.51 - 0.73]   
rs117422049 All 1.15 [0.98-1.35] BRCA1/BRCA2 2.80 [1.89 - 4.13]   
rs4879914 All 0.99 [0.96-1.02] BRCA1/BRCA2 1.30 [1.17 - 1.44]   
rs2320070 All 0.99 [0.95-1.03] BRCA1/BRCA2 1.39 [1.22 - 1.58]   
rs372812554   BRCA2 under 40y 1.75 [1.33 - 2.31] BRCA2 over 40y 0.75 [0.59 - 0.96] 
rs2109815 ER+ 1.03 [0.98-1.08] BRCA2 under 40y 1.65 [1.24 - 2.19] BRCA2 over 40y 0.75 [0.59 - 0.95] 
rs35431863 ER+ 1.01 [0.97-1.06] BRCA2 under 40y 0.55 [0.43 - 0.71] BRCA2 over 40y 1.32 [1.09 - 1.60] 
rs11255420 ER+ 0.98 [0.93-1.03] BRCA2 under 40y 0.59 [0.41 - 0.83] BRCA2 over 40y 1.55 [1.24 - 1.93] 
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